CD8A as a Prognostic and Immunotherapy Predictive Biomarker Can Be Evaluated by MRI Radiomics Features in Bladder Cancer

Abstract

As an important member of T cytotoxic pathway-related genes, CD8a molecule (CD8A) may be a useful biomarker of immunotherapeutic response and immune cell infiltration. We aimed to investigate the clinical predictive value of CD8A in prognosis and tumor microenvironment (TME) and preoperatively predict the expression of CD8A using radiogenomics in bladder cancer (BCa). Among 12 T cytotoxic pathway-related genes, CD8A was a novel protective gene and had the highest correlations with T cells and Macrophages M1 in BCa. In advanced cancer patients treated with immunotherapy, low CD8A expression was associated with immunotherapeutic failure and poor survival outcomes. CD8A expression was highly related to tumor mutation burden, critical immune checkpoint genes and several types of tumor-infiltrating immune cells, predicting effective response to immunotherapy. The preoperative MRI radiomics features and RNA-sequence data of 111 BCa samples were used to develop a radiomics signature that achieved good performance in the prediction of CD8A expression in both the training (area under curve (AUC): 0.857) and validation sets (AUC: 0.844). CD8A is a novel indicator for predicting the prognosis and immunotherapeutic response in BCa. A radiomics signature has the potential to preoperatively predict the expression of CD8A in BCa patients.

Landscape of the Immune Infiltration and Identification of Molecular Diagnostic Markers Associated With Immune Cells in Patients With Kidney Transplantation

“…Indeed, tryptophan-tRNA synthetase is overexpressed at the protein level in several cell types during antibody-mediated rejection and shows a distinct microcirculatory pattern by immunohistochemistry in antibody-mediated rejection in kidney transplantation [42] . Studies have shown that CD8A encodes the CD8 antigen, so CD8A expression may be associated with immune cell in ltration and immunotherapy response, and CD8A may serve as a useful biomarker for immunotherapy [43] . Studies have shown that CRTAM, a transmembrane protein of the immunoglobulin superfamily, can dynamically in uence adaptive immune responses [44] .…”

Development of a Molecular-Subtype-Associated Immune Prognostic Signature That Can Be Recognized by MRI Radiomics Features in Bladder Cancer

“…CD8A acts as a coreceptor with the T-cell receptors on T cells to recognize antigens displayed by antigen-presenting cells in the context of class I MHC molecules. Our previous study reported that CD8A is a novel indicator for predicting prognosis and immunotherapeutic response in BCa [ 39 ]. GNLY and FAM3B have been selected as hub genes in previous models for predicting prognosis and immunotherapy response in BCa [ 32 , 40 ], revealing the good performance of the two genes in prognostic and immunotherapy response prediction.…”

Identification of PANoptosis-relevant subgroups to evaluate the prognosis and immune landscape of patients with liver hepatocellular carcinoma

“…In bladder cancer, as a new protective gene, CD8A presented the highest correlation with T cells and M1 macrophages. Moreover, in advanced cancer patients receiving immunotherapy, it is noted that low CD8A expression showed an association with poor immunotherapy effect and survival ( Zheng et al, 2022 ). Regarding adamantinomatous craniopharyngioma, the infiltrating abundance of γδ T cells was positively correlated with CXCL6, while CD8 + T cells were negatively correlated with CXCL6 ( Lin et al, 2022 ).…”